TY - JOUR
T1 - Prognostic factors for non-metastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors
AU - Takahara, Kiyoshi
AU - Naiki, Taku
AU - Nakane, Keita
AU - Watanabe, Hiromitsu
AU - Miyake, Hideaki
AU - Koie, Takuya
AU - Yasui, Takahiro
AU - Shiroki, Ryoichi
N1 - Publisher Copyright:
© 2024 Takahara et al.
PY - 2024/10
Y1 - 2024/10
N2 - The treatment paradigm for non-metastatic castration-resistant prostate cancer (nmCRPC) has changed in recent years. An observational multicenter study was conducted to evaluate the effectiveness of androgen receptor signaling inhibitors (ARSIs) as a first-line treatment for patients with nmCRPC. The present study included native Japanese patients from four hospitals who received ARSIs as a first-line treatment for nmCRPC. The primary endpoint of the study was to evaluate the efficacy and safety of ARSI in patients with nmCRPC. The secondary endpoint was to develop a novel system to stratify the prognoses of these patients. In total, 160 patients were included in the present study. Within a median follow-up period of 23 months, the median overall survival (OS) was not reached, whereas the median progression-free survival was 26 months. Multivariate Cox regression analyses showed that the time to CRPC, prostate-specific antigen (PSA) level at the initiation of nmCRPC treatment and Geriatric Nutritional Risk Index (GNRI) were independent predictors of OS. The patients for whom information about all three independent OS predictors was available were subsequently divided into three groups as follows: Group 1, 57 patients with negative or one positive independent OS predictor; group 2, 38 patients with two positive independent OS predictors; and group 3, 10 patients with three independent OS predictors. The OS differed significantly among the three groups (P<0.0001). In conclusion, ARSIs as a first-line treatment may be associated with favorable outcomes in Japanese patients with nmCRPC. Time to CRPC, PSA level at the initiation of nmCRPC treatment and GNRI are potential predictors of OS in Japanese patients with nmCRPC who received ARSIs as a first-line treatment.
AB - The treatment paradigm for non-metastatic castration-resistant prostate cancer (nmCRPC) has changed in recent years. An observational multicenter study was conducted to evaluate the effectiveness of androgen receptor signaling inhibitors (ARSIs) as a first-line treatment for patients with nmCRPC. The present study included native Japanese patients from four hospitals who received ARSIs as a first-line treatment for nmCRPC. The primary endpoint of the study was to evaluate the efficacy and safety of ARSI in patients with nmCRPC. The secondary endpoint was to develop a novel system to stratify the prognoses of these patients. In total, 160 patients were included in the present study. Within a median follow-up period of 23 months, the median overall survival (OS) was not reached, whereas the median progression-free survival was 26 months. Multivariate Cox regression analyses showed that the time to CRPC, prostate-specific antigen (PSA) level at the initiation of nmCRPC treatment and Geriatric Nutritional Risk Index (GNRI) were independent predictors of OS. The patients for whom information about all three independent OS predictors was available were subsequently divided into three groups as follows: Group 1, 57 patients with negative or one positive independent OS predictor; group 2, 38 patients with two positive independent OS predictors; and group 3, 10 patients with three independent OS predictors. The OS differed significantly among the three groups (P<0.0001). In conclusion, ARSIs as a first-line treatment may be associated with favorable outcomes in Japanese patients with nmCRPC. Time to CRPC, PSA level at the initiation of nmCRPC treatment and GNRI are potential predictors of OS in Japanese patients with nmCRPC who received ARSIs as a first-line treatment.
KW - androgen receptor signaling inhibitor
KW - Geriatric Nutritional Risk Index
KW - multicenter retrospective cohort study
KW - non-metastatic castration-resistant prostate cancer
KW - prostate-specific antigen level
KW - time to castration-resistant prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85202553603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202553603&partnerID=8YFLogxK
U2 - 10.3892/mco.2024.2772
DO - 10.3892/mco.2024.2772
M3 - Article
AN - SCOPUS:85202553603
SN - 2049-9450
VL - 21
JO - Molecular and Clinical Oncology
JF - Molecular and Clinical Oncology
IS - 4
M1 - 74
ER -